Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

Anastasia A. Ionkina(University of Colorado Cancer Center), Jennifer R. Diamond(University of Colorado Cancer Center)

Frontiers in Oncology

May 15, 2017

10.3389/fonc.2017.00094

Cited by 22

Related Papers

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

|Breast Cancer Research|2018|69

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

|Cancers|2023|10